Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.

Leukemia research - 1 Mar 2010

Kaderi Mohd Arifin, Mansouri Mahmoud, Zainuddin Norafiza, Cahill Nicola, Gunnarsson Rebeqa, Jansson Mattias, Kimby Eva, Aleskog Anna, Lundin Jeanette, Glimelius Bengt, Melbye Mads, Juliusson Gunnar, Jurlander Jesper, Rosenquist Richard

Abstract excerpt

The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to Genes, Immunoglobulin Heavy Chain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins c-mdm2

Source

Identifiers

PMID: 19573916
DOI: 10.1016/j.leukres.2009.06.006

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.PMID 19573916Read ↗

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.Semantic proximity Read ↗

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.Semantic proximity Read ↗

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.Semantic proximity Read ↗

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Semantic proximity Read ↗

The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.Semantic proximity Read ↗

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.Semantic proximity Read ↗

No association of MDM2 SNP309 with risk of glioblastoma and prognosis.Semantic proximity Read ↗

MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients.Semantic proximity Read ↗

The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.Semantic proximity Read ↗

MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.